WuXi Biologics Reports Record 2025 Annual Results Accessibility StatementSkip Navigation HONG KONG, March 24, 2026 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development and manufacturing, today announced audited results for the year ended December 31, 2025 ("Reporting Period"). Financial Highlights Revenue: Re ...

Core Insights - WuXi Biologics has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, achieving a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, ranking first in its industry [1][1][1] Group 1: Company Performance - The company was recognized among 848 top performers out of over 9,200 companies assessed in the 2025 CSA [1][1] - WuXi Biologics' CEO, Dr. Chris Chen, emphasized the company's commitment to enhancing sustainability performance and delivering ESG excellence [1][1] Group 2: Sustainability Initiatives - WuXi Biologics is a participant in the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), advocating for sustainability [1][1] - The company has received multiple recognitions, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices [1][1][1] Group 3: Operational Overview - WuXi Biologics employs over 12,000 skilled employees across various countries and supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [1][1] - The company aims to become an ESG leader in the biologics CRDMO sector, utilizing next-generation biomanufacturing technologies and clean-energy sources [1][1]

Core Viewpoint - WuXi Biologics emphasizes its unique CRDMO (Contract Research, Development, and Manufacturing Organization) business model, highlighting its capability to deliver sustainable high growth through a scaled and integrated platform [2][4]. Business Model - The company operates a scaled, integrated CRDMO model, positioning itself as a one-stop shop for biologics manufacturing [4]. - WuXi Biologics has successfully delivered on its vision that "every biologic can be made," achieving this for every project undertaken in the past 15 years [4]. Strategic Footprint Expansion - The presentation includes updates on the company's strategic footprint expansion, although specific details are not provided in the excerpts [3]. Technology Leadership and ESG Progress - WuXi Biologics aims to showcase its technology leadership and progress in Environmental, Social, and Governance (ESG) initiatives, indicating a commitment to sustainable practices [3]. Summary and Outlook - The CEO will provide a summary and outlook for the company, suggesting a forward-looking perspective on growth and development [3].

Core Insights - WuXi Biologics has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to expand its global network and capabilities into the Middle East [1][3]. Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for the discovery, development, and manufacturing of biologics [5][6]. - The company employs over 12,000 skilled professionals across various countries, including China, the United States, Ireland, Germany, and Singapore [6]. Strategic Collaboration - The MoU facilitates the establishment of WuXi Biologics' first integrated CRDMO center in the Middle East, aiming to enhance Qatar's biotechnology sector and create a robust biopharmaceutical ecosystem [3][4]. - This partnership combines WuXi Biologics' expertise in complex biologics with Qatar's strategic vision for biopharmaceutical advancement, fostering innovation and growth [3][4]. Leadership Statements - Dr. Chris Chen, CEO of WuXi Biologics, emphasized that this partnership marks a significant step in extending the company's global capabilities and contributing to the biopharmaceutical ecosystem in Qatar [4]. - H.E. Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani, CEO of QFZ, highlighted that the collaboration strengthens Qatar's position as a reliable hub for biopharmaceutical growth, leveraging WuXi Biologics' global expertise [4]. Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone of its long-term growth strategy, focusing on green technology innovations and responsible practices across its operations [8].

Core Insights - Curia Global, Inc. has released its third Environmental, Social, and Governance (ESG) report, emphasizing its "C.U.R.I.A. Way" values: curiosity, urgency, respect, integrity, and accountability [1] - The CEO, Philip Macnabb, highlighted the company's progress as an industry leader in reducing environmental impact and fostering a culture of safety, integrity, and accountability [1] Company Overview - Curia is a contract research, development, and manufacturing organization (CDMO) with over 30 years of experience, operating in more than 20 locations globally and employing 3,200 staff [2] - The company offers a comprehensive range of services from small molecules to biologics, covering the entire process from discovery to commercialization, with capabilities in regulatory compliance, analysis, and sterile filling and packaging [2] ESG Commitments and Achievements - In 2024, Curia committed to setting near- and long-term greenhouse gas reduction targets in line with climate science through the Science Based Targets initiative (SBTi) and joined the UN's "Race to Zero" campaign [3] - Curia's facilities in France have received ISO 9001, 45001, and 14001 certifications, while its Italian facilities have achieved ISO 45001 and 14001 certifications [3] - 85% of Curia's facilities have reported no recordable injury incidents for over a year, with nine facilities achieving safety records of over two years [3] - Employees have voluntarily logged over 10,000 hours of learning on the iLearn platform, which is supported by Skillsoft's Percipio technology [3] - The Diversity, Equity, and Inclusion (DE&I) committee at Curia is actively expanding to create communication platforms and advancement opportunities for all employees [3]

Core Insights - Curia Global, Inc. has completed a $4 million investment to upgrade two sterile Active Pharmaceutical Ingredient (API) production lines in Valladolid, Spain, aligning with the latest EU GMP standards [1][2] - The investment focuses on modernizing infrastructure and technology, including the installation of new isolation devices and upgrades to HVAC, automation, and sterilization systems, aiming for a fully enclosed system to enhance product safety and prevent contamination [2][3] - Curia's commitment to quality and compliance is emphasized by CEO Philip Macnabb, highlighting the importance of reliability and precision in meeting customer needs [2][3] Investment Details - The investment primarily funds facility equipment updates and aims to support increasingly complex manufacturing projects [2][3] - Ergonomic improvements for operators and enhanced automation controls are key measures to ensure operational safety and compliance with stricter data integrity policies [2] Company Background - Curia is a contract research, development, and manufacturing organization (CDMO) with over 30 years of experience, operating a network of 20 global facilities and employing 3,200 staff [4] - The company provides comprehensive services from discovery to commercialization in small molecule drugs, generic APIs, sterile formulations, and biologics, focusing on regulatory integration and analytical testing [4]

Core Insights - WuXi Biologics has been awarded "CDMO of the Year – Asia Pacific", "Best Biologics CDMO Award: Bioprocessing", and "Best Biologics CDMO in Greater China Region" at the APBCEA 2025 [1][2] - The company has received multiple awards since 2017, highlighting its consistent excellence in the biomanufacturing sector [1][2] Company Achievements - WuXi Biologics has a portfolio of 864 integrated projects, including 168 bispecific and multispecific antibodies and 225 antibody-drug conjugates (ADCs) [3] - The development cycle for monoclonal antibody projects has been reduced to 6 months from DNA to Investigational New Drug (IND) application [3] - The company has achieved a 100% success rate in Pre-License Inspections (PLI) and has passed 44 inspections by global regulatory authorities, including 22 by the FDA and EMA [3] Leadership and Vision - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the recognition received from clients and the industry, attributing it to the company's commitment to excellence and world-class quality standards [4] - The company aims to empower partners to accelerate the delivery of groundbreaking therapies to patients globally [4] Workforce and Global Presence - WuXi Biologics employs over 12,000 skilled professionals across China, the United States, Ireland, Germany, and Singapore [6] - The company supports 864 integrated client projects, with 24 currently in commercial manufacturing as of June 30, 2025 [6] Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone for long-term growth, focusing on green technology innovations and responsible practices [7] - The company collaborates with stakeholders to create positive social and environmental impacts while promoting excellence in Environment, Social, and Governance (ESG) [7]

Core Insights - Sai Life Sciences Limited reported strong financial performance for Q1FY26, with revenue reaching ₹496 crore, a 77% increase year-over-year, driven by growth in the CDMO segment [1][2][8] - The company achieved an EBITDA of ₹125 crore, reflecting a 305% increase compared to the same quarter last year, with an EBITDA margin of 25% [2][6][8] - Net profit for the quarter was ₹60 crore, a significant turnaround from a loss of ₹13 crore in Q1FY25, resulting in a PAT margin of 12% [2][6][8] Financial Performance - Revenue from Operations: ₹496 crore in Q1FY26 compared to ₹280 crore in Q1FY25, a 77% increase [2][6] - EBITDA: ₹125 crore in Q1FY26, up from ₹31 crore in Q1FY25, a 303% increase [2][6] - EBITDA Margin: Expanded to 25% in Q1FY26 from 11% in Q1FY25 [2][6] - Profit Before Tax (PBT): ₹81 crore in Q1FY26, compared to a loss of ₹18 crore in Q1FY25 [2][6] - Profit After Tax (PAT): ₹60 crore in Q1FY26, compared to a loss of ₹13 crore in Q1FY25 [2][6] Business Highlights - The company inaugurated new Biology Labs and a Peptide Research Center, enhancing its Integrated Discovery platform [6][9] - Commenced commercial operations at Bidar Unit IV, increasing total manufacturing capacity to approximately 700 KL [6][9] - Invested ₹134 crore in capital expenditure during Q1FY26, focusing on R&D infrastructure and process development capabilities [6][9] - Onboarded 253 scientists and technical staff to support scaling operations [6][9] Strategic Focus - The company is committed to advancing innovation in complex science and enhancing client partnerships [5][7] - Plans to build additional production capacity at Unit IV, Bidar, expected to be ready by Q3FY27 [6][9] - Ongoing construction of a new Medicinal Chemistry block to support early-phase peptide development and clinical formulations [6][9]